RESULTS:
The Vortex dual-lumen port generated pressure alarms above flow rates of 60 mL/minute. Throughout flow rates from 5 to 100 mL/minute, the Trifusion catheter and the TidalPort device operated at lower pressures than the Vortex ports. Within typical clinical flow rates, neither catheter material nor internal diameter substantially affected pressure.
CONCLUSION:
Central venous access devices show large differences in pressure within flow rates used routinely in clinical settings. These differences cannot be fully attributed to catheter material composition or catheter internal diameter. E xtracorporeal photopheresis (ECP) combines apheresis and photodynamic therapy to induce immunomodulation for the treatment of graftversus-host disease, systemic sclerosis, solid organ transplant rejection, Crohn's disease, and various other diseases.
1 ECP procedures take from 1 hour to several hours, and patients undergo these procedures for weeks or months, depending on indication and treatment response. Although peripheral access is preferred, the repeated, prolonged venous access required for ECP often necessitates the use of an implantable vascular access device (IVAD), tunneled central venous catheter (TCVC), or tunneled central venous catheter with port (port-CVC).
The need for central access is especially common in elderly patients or those with phlebitis from frequent intravenous use. 2 Although not well-studied in the context of ECP, device-related complications, reduced patency, and secondary removal of IVADs are common. 3 Until recently, no IVAD was US Food and Drug Administration-approved for use in ECP, and published research on the performance and safety of IVADs in ECP is lacking. IVADs vary in their design and material composition, and these differences may affect device performance, such as the ability to maintain desired flow rate, the development of fibrin sheath, or clot formation. These differences in device performance, in turn, may affect clinical outcomes, such as procedure duration, frequency of malfunction, use of thrombolytics, and short-term and long-term device patency. 4 Anecdotally, our apheresis center has noted that ECP procedures are frequently prolonged by device occlusion and high-pressure alarms. Given the increasing prevalence of IVAD use for ECP and the lack of knowledge about how well these devices perform, we compared the performance of several common IVADs in an ex vivo system.
MATERIALS AND METHODS
To study differences in IVAD performance during ECP, the ECP procedure was replicated in an ex vivo system. Devices tested were the Vortex single-lumen and dual lumen port-CVCs (Angiodynamics), the TidalPort port-CVC (Norfolk), and the Trifusion TCVC (Hickman) ( Table 1) . Vortex ports and Trifusion catheters have been used at our facility for over 5 years. The TidalPort is a newer device and has not yet been used clinically at our facility.
Each device was tested on both the inlet and return circuits of a Cellex closed photopheresis system (Mallinckrodt). Devices were mounted on a wooden frame, and IVADs were accessed with a 16-gauge, non-coring Huber point needle or, for the Trifusion catheters, were connected directly to the infusion lines. All devices were connected to the Cellex system with LifePort infusion set tubing (Angiodynamics).
Heparinized, nonexpired donor red blood cells (RBCs) were diluted to 35% hematocrit with normal saline and warmed to 388C in a hot water bath. IVAD catheter tips were immersed in the reservoir of heparinized, diluted RBCs. While blood from the reservoir was circulated by the Cellex machine, inlet, return, and centrifuge pressures were recorded at flow rates from 5 mL/minute to 100 mL/minute.
The primary objective of the study was to compare inlet and return pressures between IVAD devices. When testing each device, pressures were recorded over 2 minutes in both inlet and return circuits at each flow rate. Pressure and flow rate data were recorded directly from the Cellex machine display. To verify Cellex machine pressure values, pressure was recorded simultaneously with an in-line pressure transducer for some experiments. Polyurethane and silicone catheters were compared, and polyurethane catheters with internal diameters of 1.33 mm and 1.66 mm were compared for the same device. All data were analyzed in R version 3.4.1, 5 and figures were generated with the ggplot2 package. 6 
RESULTS

Confirmation with external pressure transducer
To confirm that the Cellex generated consistent pressures at a given flow rate, pressures were recorded with an inline pressure transducer. Using a Trifusion TCVC, pressures were measured every 300 msec at three separate inlet flow rates ( Fig. 1A ). At flow rates of 20 mL/minute, 40 mL/minute, and 60 mL/minute, the mean 6 standard deviation recorded pressures were 26.9 6 13 mmHg, 238.0 6 2.8 mmHg, and 271.8 6 2.6 mmHg, respectively. For subsequent experiments, pressures were recorded directly from Cellex display.
To assess the accuracy of Cellex pressure measurements, Cellex reported pressures were compared with simultaneously recorded pressures from the in-line pressure transducer at inlet flow rates of 20 mL/minute, 40 mL/minute, and 60 mL/minute using a Trifusion catheter (Fig. 1B) . At least 100 readings were taken at each flow rate. Pressures were comparable for the Cellex system and the transducer (standard deviations were 6 7.0 mmHg, 6 10.5 mmHg, and 6 7.8 mmHg for flow rates of 20 mL/minute, 40 mL/minute, and 60 mL/minute, respectively).
Device inlet and return pressures
Inlet and return pressures were recorded through a broad range of flow rates for each device (Fig. 2) . Trifusion TCVC, TidalPort, and Vortex single-lumen port devices were able to maintain function up to flow rates of 100 mL/minute, while high-pressure alarms from the Cellex device interrupted trials of the dual-lumen Vortex port at flow rates above 60 mL/minute. Both inlet and return pressures showed a strong linear relationship to flow rate (r 5 0.96-0.99). At each tested flow rate, the Trifusion catheter and the TidalPort device consistently generated lower pressures compared with the Vortex devices.
Comparison of catheter material
The TidalPort device uses a polyurethane catheter. The Vortex single-lumen port may utilize either a polyurethane or silicone catheter, and the Vortex dual-lumen port uses a silicone catheter. Using a TidalPort device, polyurethane and silicone catheters were compared in the ex vivo system to test the effect of catheter material on pressureflow relationships. TidalPort devices were used with both materials, so that, other than the catheters, the circuits were identical. Both catheters had an internal diameter of 1.3 mm and a length of 76 cm. Over a broad range of flow rates, inlet and return pressures were comparable between the two catheter materials (Fig. 3) .
Comparison of catheter diameter
The TidalPort catheter has an internal lumen diameter of 1.66 mm, whereas catheters for Vortex devices have internal diameters of 1.33 mm. Using the TidalPort device, 1.33-mm and 1.66-mm diameter catheters were compared. Across all flow rates, catheter diameter did not significantly affect outlet pressure (Fig. 4) . The smaller lumen did generate substantially different inlet pressures at flow rates above 50 mL/minute. At 50 mL/minute, there was a 5% difference in pressure between the two diameters; and, at 100 mL/minute, this difference was 40%. However pressures were comparable within the range of routinely used flow rates (range, 30-50 mL/minute).
DISCUSSION
This report is the first published ex vivo comparison of IVADs in the Cellex ECP system. Similar ex vivo experiments have been reported previously. St€ ander and colleagues measured flow rates at various pressures for eight central venous catheters but no port devices using the UVAR closed ECP system (Therakos) with a glucose solution of similar viscosity to blood. 7 They found that the flow rate depended primarily on catheter length, where catheters less than 48 cm in length achieved flow rates of up to 28 mL/minute. The flow rate was influenced to a lesser extent by catheter internal diameter. Similarly, when varying the flow rate, we observed that larger lumen catheters were associated with lower pressures at flow rates that exceeded 30 mL/minute (Fig. 4A) . All of these findings are expected based on the Hagen-Poiseuille law, in which flow varies directly with vessel radius and, inversely, with vessel length. It is important to note that catheters are trimmed during placement for each patient, making catheter length the least predictable variable determining device performance. Peterson and coworkers presented an ex vivo study comparing the Vortex single-lumen port with the Norfolk SportPort (later renamed TidalPort) using diluted RBC units in a Spectra Optia machine (Terumo). 8 Similar to our findings, those authors reported that the TidalPort had substantially lower inlet and return pressures compared with the Vortex port. Peterson and colleagues' abstract also indicated that the Vortex single-lumen device failed to sustain flow rates above 90 mL/minute with the Optia platform. We found that the single-lumen Vortex functioned throughout the entire range of flow rates tested (range, 5-100 mL/minute) (Fig. 2) , but the duallumen Vortex port triggered pressure alarms above 60 mL/ minute. All of these ex vivo studies have similar limitations. They cannot account for patient differences in physiology or complications such as catheter kinking, fibrin deposition, or occluding thrombi. We chose saline-diluted RBCs as a medium with physical properties similar to those of whole blood. Previous ex vivo studies also have used saline-diluted RBCs 8 or 40% glucose. 7 It is possible that device performance could be affected by the plasma component of whole blood. However, occlusion and fibrin deposition typically manifest over chronic use and would not be expected to influence a single procedure as modeled here. The performance differences found in this study could cause increased procedure times. For example, if inlet pressures were limited to 100 mmHg, then the Vortex single-lumen, Trifusion, and TidalPort devices all could operate at the maximum flow rate of clinical procedures, 50 mL/minute, whereas the Vortex dual-lumen would be limited to 30 mL/minute ( Fig. 2A) . For a processed volume of 1.5 liters, this difference would increase procedure time by 20 minutes. Although small, this difference likely underestimates the real increase in procedure time where higher operating pressures are more likely stop procedures by system alarms.
These limitations in replicating clinical device performance highlight the need to compare devices in prospective, randomized patient trials. However, currently, there are few clinical trials comparing central venous access in ECP. Trials of IVADs for other procedures also are sparse and may not be applicable to the dwell time and flow rates required for ECP. A retrospective study of duallumen Vortex ports in chronic RBC exchange, a procedure with similar mechanical demands, did indicate that the Vortex ports had longer procedure duration, lower inlet speed, and greater complication rates than peripheral or temporary central venous catheters. Overall, this study demonstrates substantial differences in the performance of central venous access devices in an ex vivo model of ECP. The Trifusion catheter and the TidalPort device consistently operated at lower pressures than the Vortex ports. Although ex vivo comparisons are useful, prospective clinical trials also are needed to make meaningful comparisons of venous access in ECP.
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